QR Code

Antitumor activity of rucaparib plus PLX038A in serous endometrial carcinoma

Abstract Background Serous endometrial cancer (SEC) is a genomically and morphologically distinct endometrial cancer (EC) subtype with a poor progression-free and overall survival. The development of novel therapies is needed to improve outcomes. Methods We used serous and serous-like EC patient-der...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Xiaonan Hou, Valentina Zanfagnin, Conway Xu, Erik Jessen, Yuanhang Liu, Chen Wang, Yajue Huang, Shaun D. Fontaine, Daniel V. Santi, Gerardo Colon-Otero, Sarah E. Gill, Gretchen E. Glaser, Kristina A. Butler, Jamie N. Bakkum-Gamez, Sean C. Dowdy, Ann L. Oberg, Melissa C. Larson, Hunter J. Atkinson, Laura N. Duffield, Kevin L. Peterson, Scott H. Kaufmann, S. John Weroha
Hōputu: Artigo
Reo:Inglês
I whakaputaina: BMC 2025-05-01
Rangatū:Journal of Experimental & Clinical Cancer Research
Ngā marau:
Endometrial cancer
Xenografts
PARP inhibitor
Rucaparib
Homologous recombination
DNA repair
Urunga tuihono:https://doi.org/10.1186/s13046-025-03406-7
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite